Managing Recurrent SCCHN in The Era of Immunotherapy:
Opportunities and Hurdles in Daily Clinical Practice

More details

Hot Topics in the Management of Advanced Non-Small Cell Lung Cancer:
Expert Insights on Recent Advances

Lung Cancer

More details

Join the ACE Oncology Network Today!

Discover the latest updates in oncology, and engage with experts in the field.

JOIN ACE ONCOLOGY NOW

Upcoming Events

See All Upcoming Events
Managing Recurrent SCCHN in The Era of Immunotherapy:<br>Opportunities and Hurdles in Daily Clinical Practice

Managing Recurrent SCCHN in The Era of Immunotherapy:
Opportunities and Hurdles in Daily Clinical Practice

The management of recurrent/metastatic (R/M) squamous cell cancer of the...

Coming Soon

Frequently Asked Questions on Managing NSCLC With Rare Oncogenic Drivers

Frequently Asked Questions on Managing NSCLC With Rare Oncogenic Drivers

Register now

The Power of Precision Medicine in Advanced Non-Small Cell Lung Cancer: <br/> Focus on Targeting MET Alterations

The Power of Precision Medicine in Advanced Non-Small Cell Lung Cancer:
Focus on Targeting MET Alterations

In the era of precision medicine, detecting genomic alterations is...

Online Education

See All Online Education
article-thumbnail

On-Demand Presentations and Slides

Hot Topics in the Management of Advanced Non-Small Cell Lung Cancer:
Expert Insights on Recent Advances

7 videos / 4 slide decks
article-thumbnail

On-Demand Presentations and Slides

Integration of New Biomarkers and Targeted Therapy in Advanced NSCLC: Challenges and Solutions

4 videos / 4 slide decks
article-thumbnail

On-Demand Presentations and Slides

Optimizing Personalized Care of Patients With Colorectal Cancer

9 videos / 7 slide decks
article-thumbnail

On-Demand Presentations and Slides

Guidelines & Beyond in Colorectal Cancer

9 videos / 7 slide decks

Latest Blogs

See Latest Blogs
An Awareness of Delayed irAEs After Anti-PD1 Therapy is Needed

An Awareness of Delayed irAEs After Anti-PD1 Therapy is Needed

Immune checkpoint inhibitors (ICIs) have changed the treatment armamentarium and...
FDA Cancer Therapy Approvals in March 2021

FDA Cancer Therapy Approvals in March 2021

In March, the US Food and Drug Administration (FDA) granted...
Lenvatinib/Pembrolizumab Combo Justified for Endometrial Cancer

Lenvatinib/Pembrolizumab Combo Justified for Endometrial Cancer

The prognosis for patients with advanced or recurrent endometrial cancer...
The Clinical Utility of Genomic Testing in Advanced Solid Tumors

The Clinical Utility of Genomic Testing in Advanced Solid Tumors

Developments in next-generation sequencing (NGS) and other molecular profiling technologies...